Efficiency and Safety Study of Pegylated Somatropin to Treat Growth Hormone Deficiency Children
Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
The purpose of the multicenter, randomized, open-label, controlled phase II study is to
determine whether pegylated recombinant human growth hormone is effective in the treatment of
children with growth hormone deficiency.
Phase:
Phase 2
Details
Lead Sponsor:
GeneScience Pharmaceuticals Co., Ltd.
Collaborators:
Capital Medical University Children's Hospital of Fudan University First Affiliated Hospital, Sun Yat-Sen University Huazhong University of Science and Technology